• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

250.69 -3.15 (-1.24%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,157,377
Open 251.68
Bid (Size) 250.00 (100)
Ask (Size) 253.50 (100)
Prev. Close 253.84
Today's Range 246.15 - 252.44
52wk Range 138.00 - 254.41
Shares Outstanding 146,800,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
S&P 500 Top Movers: Gainers and Losers From Today's US Session ↗
October 20, 2026
Via Chartmill
Topics Stocks
News headline image
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
October 19, 2026
From Biogen Inc.
Via GlobeNewswire

Performance

52-Week Range 1.5% below 52-week high
250.69
138.0052W Low 254.4152W High
1 Week 1.5% below 1-week high
231.041W Low 254.411W High

Biogen Idec (BIIB) traded between $138.00 and $254.41 over the past 52 weeks and last traded at $250.69, 1.5% below its 52-week high. Over the past week it ranged between $231.04 and $254.41.

Past 12 Months
+7.4%
+10.7%
+25.3%
+38.8%
+41.0%
+67.2%
1W +$17.21
1M +$24.33
3M +$50.55
6M +$70.02
YTD +$72.87
1Y +$100.80

BIIB was +67.2% over the past year, +38.8% over six months, +41.0% year to date, +7.4% in the last week.

12 Months vs Market
BIIB
+67.2%
DIA
+10.4%
SPY
+12.2%
QQQ
+14.1%
IWM
+10.6%

Over the past 12 months BIIB returned +67.2% versus DIA (Dow) +10.4%, SPY (S&P 500) +12.2%, QQQ (Nasdaq 100) +14.1% and IWM (Russell 2000) +10.6%.

Volume & Liquidity 1.11× 3-mo avg
Today 1,157,377 3-mo avg 1.0M
1W
1.3M
1M
1.3M
3M
1.0M
6M
1.1M
YTD
1.2M
1Y
1.4M

BIIB most recently traded 1,157,377 shares against a 3-month average daily volume of 1.0M.

More News

Read More
News headline image
Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
October 14, 2026
Via StockStory
Topics Artificial Intelligence
Discover which S&P500 stocks are making waves on Monday. ↗
October 12, 2026
Via Chartmill
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
October 12, 2026
Via Chartmill
News headline image
Biogen (BIIB) Stock Is Up, What You Need To Know
October 12, 2026
Via StockStory
Topics Earnings
News headline image
2 Surging Stocks for Long-Term Investors and 1 We Brush Off
October 12, 2026
Via StockStory
Topics Economy Energy
News headline image
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
October 07, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
October 02, 2026
From Biogen Inc.
Via GlobeNewswire
News headline image
1 Profitable Stock Worth Investigating and 2 We Ignore
October 01, 2026
Via StockStory
News headline image
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
September 30, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
September 24, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks
September 23, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
September 21, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
September 17, 2026
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗
September 15, 2026
Via MarketBeat
News headline image
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology ↗
September 12, 2026
Via MarketBeat
Thursday's session: top gainers and losers in the S&P500 index ↗
September 10, 2026
Via Chartmill
News headline image
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
September 09, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
September 08, 2026
Via StockStory
Topics Artificial Intelligence
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 08, 2026
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 08, 2026
From BioMedWire
Via GlobeNewswire

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 250.69
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 10/23/26 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 36.80B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 37B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap